Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Toogeh G, Ferdowsi S, Naadali F, Alimoghaddam K, Ghavamzadeh A, Shirkoohi R, Ghaffari SH.

Med Oncol. 2011 Dec;28(4):1555-8. doi: 10.1007/s12032-010-9570-8. Epub 2010 May 25.

PMID:
20499211
2.

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N.

Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5.

PMID:
20047097
3.

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.

Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.

Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.

PMID:
22847163
4.

JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.

Yoo JH, Park TS, Maeng HY, Sun YK, Kim YA, Kie JH, Cho EH, Song J, Lee KA, Suh B, Choi JR.

Cancer Genet Cytogenet. 2009 Feb;189(1):43-7. doi: 10.1016/j.cancergencyto.2008.09.010. Review.

PMID:
19167611
5.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
6.

Transformation of polycythemia vera to chronic myelogenous leukemia.

Mirza I, Frantz C, Clarke G, Voth AJ, Turner R.

Arch Pathol Lab Med. 2007 Nov;131(11):1719-24.

PMID:
17979493
7.

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST.

Blood Cancer J. 2015 Oct 2;5:e351. doi: 10.1038/bcj.2015.77. No abstract available.

8.

[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].

Takizawa M, Yokohama A, Sekigami T, Koiso H, Ishizaki T, Mitsui T, Ogawa Y, Saitoh T, Handa H, Tsukamoto N, Murakami H, Nojima Y.

Rinsho Ketsueki. 2014 Jun;55(6):687-91. Japanese.

PMID:
24975338
9.

JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.

Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, Xu W, Li J.

Leuk Lymphoma. 2008 Apr;49(4):696-9. doi: 10.1080/10428190701885537.

PMID:
18398736
10.
11.

A resequencing program in India detects the rare JAK2 L579F mutation in patients suffering from polycythemia vera and negative for JAK2 V617F.

Acharya A, Vaniawala S, Parekh H, Sheikh H, Patel H, Ali R, Khan A, Nagee A, Kunjadia P, Mukhopadhyaya PN.

Int J Lab Hematol. 2014 Aug;36(4):e30-3. doi: 10.1111/ijlh.12141. Epub 2013 Sep 6. No abstract available.

PMID:
24033912
13.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

14.

Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, Bendit I.

Int J Hematol. 2008 Sep;88(2):243-5. doi: 10.1007/s12185-008-0131-2. Epub 2008 Jul 16. No abstract available.

PMID:
18626727
15.

The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.

Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M, Qualtieri G, Bisconte MG, Naccarato M, Gentile C, Laganà C, Romeo F, Neri A, Nobile F, Morabito F.

Leuk Lymphoma. 2008 Oct;49(10):1907-15. doi: 10.1080/10428190802290652.

PMID:
18720212
16.

JAK2 V617F mutation is rare in idiopathic erythrocytosis: a difference from polycythemia vera.

Yoshinaga K, Mori N, Wang YH, Tomita K, Shiseki M, Motoji T.

Int J Hematol. 2008 Jul;88(1):82-7. doi: 10.1007/s12185-008-0103-6. Epub 2008 Jun 6.

PMID:
18528646
17.

Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.

Cappetta M, Pérez V, Zubillaga MN, Elizondo V, Manrique G, Prosper I, Boschi S, Bonomi R, Pomoli S, Díaz L, Martínez L, Uriarte MR.

Int J Lab Hematol. 2013 Feb;35(1):e4-5. doi: 10.1111/ijlh.12010. Epub 2012 Oct 13. No abstract available.

PMID:
23062104
18.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
19.

Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.

Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K, Tomoyasu S.

Int J Hematol. 2008 Sep;88(2):181-8. doi: 10.1007/s12185-008-0129-9. Epub 2008 Jul 10.

PMID:
18612778
20.

Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.

Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJ, Green AR, Alexander DR.

N Engl J Med. 2008 Dec 25;359(26):2778-89. doi: 10.1056/NEJMoa0804953.

Supplemental Content

Support Center